<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067699</url>
  </required_header>
  <id_info>
    <org_study_id>VitD&amp;PV</org_study_id>
    <nct_id>NCT05067699</nct_id>
  </id_info>
  <brief_title>Vitamin D Level in Recurrent PV</brief_title>
  <official_title>Serum Vitamin D Level Detection in Patients With Recurrent Pityriasis Versicolor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <brief_summary>
    <textblock>
      Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the&#xD;
      evaluation of vitamin D level.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25(OH) D3 level</measure>
    <time_frame>6months-1 year</time_frame>
    <description>The serum of patients and controls will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Recurrent Pityriasis Versicolor</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>recurrent pityriasis versicolor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy age and sex matched</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)</intervention_name>
    <description>The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recurrent Pityriasis Versicolor (more than 2 attacks per year) and of a&#xD;
        disseminated nature&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Patients with recurrent pityriasis versicolor (active now) and not taking treatment&#xD;
             for it.&#xD;
&#xD;
          -  Patients of both genders.&#xD;
&#xD;
          -  Age ≥18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Patients with other cutaneous diseases.&#xD;
&#xD;
          -  Patient's having dandruff (scaly scalp) even if not symptomatizing.&#xD;
&#xD;
          -  Pregnant and lactating females, children, prisoners, cognitively impaired or mentally&#xD;
             disabled subjects.&#xD;
&#xD;
          -  Patients with autoimmune diseases.&#xD;
&#xD;
          -  Patients with immunodeficiency diseases.&#xD;
&#xD;
          -  Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients&#xD;
             taking immunosuppressive drugs e.g. chemotherapy, cortisone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rana Hilal, M.D</last_name>
    <phone>+201001488869</phone>
    <email>rana.hilal@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr Al Ainy Teaching Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rana Hilal, M.d</last_name>
      <phone>1001488869</phone>
      <email>rana.hilal@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Rana F Hilal, MD</investigator_full_name>
    <investigator_title>Lecturer of Dermatology, faculty of Medicine, Cairo University.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea Versicolor</mesh_term>
    <mesh_term>Pityriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

